(4R)-limonene

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
(4R)-limonene
Accession Number
DB08921
Type
Small Molecule
Groups
Investigational
Description

Limonene is common in cosmetic products. As the main odor constituent of citrus (plant family Rutaceae), D-limonene is used in food manufacturing and some medicines, e.g. as a flavoring to mask the bitter taste of alkaloids, and as a fragrant in perfumery.

Structure
Thumb
Synonyms
  • (+)-(4R)-Limonene
  • (+)-(R)-Limonene
  • (+)-4-isopropenyl-1-methylcyclohexene
  • (+)-Limonene
  • (4R)-1-methyl-4-isopropenylcyclohex-1-ene
  • (4R)-4-isopropenyl-1-methylcyclohexene
  • (R)-(+)-limonene
  • (R)-(+)-p-mentha-1,8-diene
  • (R)-1-methyl-4-(1-methylethenyl)cyclohexene
  • (R)-4-isopropenyl-1-methyl-1-cyclohexene
  • (R)-p-mentha-1,8-diene
  • 4βH-p-mentha-1,8-diene
  • D-(+)-limonene
  • D-Limonen
  • D-limonene
External IDs
FEMA NO. 2633
Categories
UNII
GFD7C86Q1W
CAS number
5989-27-5
Weight
Average: 136.234
Monoisotopic: 136.125200512
Chemical Formula
C10H16
InChI Key
XMGQYMWWDOXHJM-JTQLQIEISA-N
InChI
InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,10H,1,5-7H2,2-3H3/t10-/m0/s1
IUPAC Name
(4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-1-ene
SMILES
CC(=C)[C@@H]1CCC(C)=CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with 5-androstenedione.Experimental, Illicit
Abciximab(4R)-limonene may increase the anticoagulant activities of Abciximab.Approved
Acebutolol(4R)-limonene may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Acemetacin.Approved, Experimental, Investigational
Acenocoumarol(4R)-limonene may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with (4R)-limonene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Alendronic acid.Approved
Aliskiren(4R)-limonene may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Alminoprofen.Experimental
Alprenolol(4R)-limonene may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with (4R)-limonene.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Amcinonide.Approved
Amikacin(4R)-limonene may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
Amiloride(4R)-limonene may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Aminosalicylic Acid.Approved
Amiodarone(4R)-limonene may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
Ancrod(4R)-limonene may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with (4R)-limonene.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Antipyrine.Approved, Investigational
Antithrombin III human(4R)-limonene may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Antrafenine.Approved
Apixaban(4R)-limonene may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Apocynin.Investigational
Apramycin(4R)-limonene may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with (4R)-limonene.Approved, Investigational
Arbekacin(4R)-limonene may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
Ardeparin(4R)-limonene may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
Argatroban(4R)-limonene may increase the anticoagulant activities of Argatroban.Approved, Investigational
Arotinolol(4R)-limonene may decrease the antihypertensive activities of Arotinolol.Investigational
Asenapine(4R)-limonene may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Atamestane.Investigational
Atenolol(4R)-limonene may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with (4R)-limonene.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with (4R)-limonene.Approved
Azficel-TThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with (4R)-limonene.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with (4R)-limonene.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Balsalazide.Approved, Investigational
Becaplermin(4R)-limonene may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Beclomethasone dipropionate.Approved, Investigational
Befunolol(4R)-limonene may decrease the antihypertensive activities of Befunolol.Experimental
Bekanamycin(4R)-limonene may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with (4R)-limonene.Approved
BenorilateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with (4R)-limonene.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with (4R)-limonene.Approved
BenzydamineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with (4R)-limonene.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Betamethasone.Approved, Vet Approved
Betaxolol(4R)-limonene may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with (4R)-limonene.Approved, Investigational
Bevantolol(4R)-limonene may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with (4R)-limonene.Approved, Investigational
Bisoprolol(4R)-limonene may decrease the antihypertensive activities of Bisoprolol.Approved
Bivalirudin(4R)-limonene may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
Bopindolol(4R)-limonene may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bucillamine.Investigational
Bucindolol(4R)-limonene may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bufexamac.Approved, Experimental
Bufuralol(4R)-limonene may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with (4R)-limonene.Approved
Bupranolol(4R)-limonene may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with (4R)-limonene.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with (4R)-limonene.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with (4R)-limonene.Approved
CarprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Carprofen.Approved, Vet Approved, Withdrawn
Carteolol(4R)-limonene may decrease the antihypertensive activities of Carteolol.Approved
Carvedilol(4R)-limonene may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with (4R)-limonene.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Celecoxib.Approved, Investigational
Celiprolol(4R)-limonene may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
Certoparin(4R)-limonene may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with (4R)-limonene.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with (4R)-limonene.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with (4R)-limonene.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of (4R)-limonene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Cimicoxib.Investigational
Cinoxacin(4R)-limonene may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Ciprofloxacin(4R)-limonene may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Cisplatin.Approved
Citric Acid(4R)-limonene may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with (4R)-limonene.Vet Approved
Cloranolol(4R)-limonene may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of (4R)-limonene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of (4R)-limonene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with (4R)-limonene.Experimental
Cyclosporine(4R)-limonene may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilate(4R)-limonene may increase the anticoagulant activities of Dabigatran etexilate.Approved
Dalteparin(4R)-limonene may increase the anticoagulant activities of Dalteparin.Approved
Danaparoid(4R)-limonene may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
Darexaban(4R)-limonene may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Delapril.Experimental
Desipramine(4R)-limonene may decrease the antihypertensive activities of Desipramine.Approved, Investigational
Desirudin(4R)-limonene may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with (4R)-limonene.Approved, Investigational
Dextran(4R)-limonene may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dibekacin(4R)-limonene may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with (4R)-limonene.Approved, Vet Approved
Dicoumarol(4R)-limonene may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with (4R)-limonene.Approved
Dihydrostreptomycin(4R)-limonene may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with (4R)-limonene.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with (4R)-limonene.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with (4R)-limonene.Approved
Drospirenone(4R)-limonene may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when (4R)-limonene is combined with E-6201.Investigational
Edetic Acid(4R)-limonene may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
Edoxaban(4R)-limonene may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Enalaprilat.Approved
Enoxacin(4R)-limonene may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
Enoxaparin(4R)-limonene may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with (4R)-limonene.Experimental
Epanolol(4R)-limonene may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with (4R)-limonene.Experimental
Eplerenone(4R)-limonene may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with (4R)-limonene.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with (4R)-limonene.Approved
EquileninThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Equilin.Approved
Esatenolol(4R)-limonene may decrease the antihypertensive activities of Esatenolol.Experimental
Esmolol(4R)-limonene may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with (4R)-limonene.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ethenzamide.Experimental
Ethyl biscoumacetate(4R)-limonene may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with (4R)-limonene.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with (4R)-limonene.Experimental
FenbufenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with (4R)-limonene.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Feprazone.Experimental
Ferulic acid(4R)-limonene may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with (4R)-limonene.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fish oil.Approved, Nutraceutical
Fleroxacin(4R)-limonene may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with (4R)-limonene.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fludrocortisone.Approved, Investigational
Fluindione(4R)-limonene may increase the anticoagulant activities of Fluindione.Approved, Investigational
Flumequine(4R)-limonene may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with (4R)-limonene.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with (4R)-limonene.Approved, Nutraceutical, Vet Approved
Fondaparinux(4R)-limonene may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodium(4R)-limonene may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with (4R)-limonene.Experimental
FormestaneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Fosinopril.Approved
Framycetin(4R)-limonene may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with (4R)-limonene.Approved, Vet Approved
Gabexate(4R)-limonene may increase the anticoagulant activities of Gabexate.Investigational
Garenoxacin(4R)-limonene may increase the neuroexcitatory activities of Garenoxacin.Investigational
Gatifloxacin(4R)-limonene may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with (4R)-limonene.Approved, Withdrawn
Gemifloxacin(4R)-limonene may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
Geneticin(4R)-limonene may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
Gentamicin(4R)-limonene may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1A(4R)-limonene may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ginseng.Approved, Investigational, Nutraceutical
Grepafloxacin(4R)-limonene may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when (4R)-limonene is combined with HE3286.Investigational
Heparin(4R)-limonene may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Higenamine.Investigational
Hydralazine(4R)-limonene may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with (4R)-limonene.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with (4R)-limonene.Approved, Investigational
Hygromycin B(4R)-limonene may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with (4R)-limonene.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Icosapent.Approved, Nutraceutical
Idraparinux(4R)-limonene may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with (4R)-limonene.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with (4R)-limonene.Approved
Indenolol(4R)-limonene may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with (4R)-limonene.Approved, Investigational
Isepamicin(4R)-limonene may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Istaroxime.Investigational
Kanamycin(4R)-limonene may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with (4R)-limonene.Approved
Labetalol(4R)-limonene may decrease the antihypertensive activities of Labetalol.Approved
Landiolol(4R)-limonene may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with (4R)-limonene.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with (4R)-limonene.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with (4R)-limonene.Approved, Investigational
Lepirudin(4R)-limonene may increase the anticoagulant activities of Lepirudin.Approved
Letaxaban(4R)-limonene may increase the anticoagulant activities of Letaxaban.Investigational
Levobetaxolol(4R)-limonene may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
Levobunolol(4R)-limonene may decrease the antihypertensive activities of Levobunolol.Approved
Levofloxacin(4R)-limonene may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with (4R)-limonene.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with (4R)-limonene.Approved
Lomefloxacin(4R)-limonene may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with (4R)-limonene.Approved
LoteprednolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with (4R)-limonene.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with (4R)-limonene.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with (4R)-limonene.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when (4R)-limonene is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Mefenamic acid.Approved
Melagatran(4R)-limonene may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Meloxicam.Approved, Vet Approved
Mepindolol(4R)-limonene may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with (4R)-limonene.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with (4R)-limonene.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with (4R)-limonene.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Methylprednisolone.Approved, Vet Approved
Metipranolol(4R)-limonene may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with (4R)-limonene.Approved
Metoprolol(4R)-limonene may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
Micronomicin(4R)-limonene may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with (4R)-limonene.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with (4R)-limonene.Approved
MizoribineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with (4R)-limonene.Approved
Moxifloxacin(4R)-limonene may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with (4R)-limonene.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with (4R)-limonene.Approved
NabumetoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Nabumetone.Approved
Nadolol(4R)-limonene may decrease the antihypertensive activities of Nadolol.Approved
Nadroparin(4R)-limonene may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Nafamostat(4R)-limonene may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with (4R)-limonene.Approved
Nalidixic Acid(4R)-limonene may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when (4R)-limonene is combined with NCX 1022.Investigational
Neamine(4R)-limonene may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
Nebivolol(4R)-limonene may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
Nemonoxacin(4R)-limonene may increase the neuroexcitatory activities of Nemonoxacin.Investigational
Neomycin(4R)-limonene may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Nepafenac.Approved, Investigational
Netilmicin(4R)-limonene may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Nitroaspirin.Investigational
Norfloxacin(4R)-limonene may increase the neuroexcitatory activities of Norfloxacin.Approved
Ofloxacin(4R)-limonene may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with (4R)-limonene.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with (4R)-limonene.Approved
Olsalazine(4R)-limonene may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when (4R)-limonene is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Orgotein.Vet Approved
Otamixaban(4R)-limonene may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Oxaprozin.Approved
Oxolinic acid(4R)-limonene may increase the neuroexcitatory activities of Oxolinic acid.Experimental
Oxprenolol(4R)-limonene may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with (4R)-limonene.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Parecoxib.Approved
Paromomycin(4R)-limonene may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Parthenolide.Approved, Investigational
Pazufloxacin(4R)-limonene may increase the neuroexcitatory activities of Pazufloxacin.Investigational
Pefloxacin(4R)-limonene may increase the neuroexcitatory activities of Pefloxacin.Approved
Penbutolol(4R)-limonene may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol Tetranitrate(4R)-limonene may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan Polysulfate(4R)-limonene may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Perindopril.Approved
Phenindione(4R)-limonene may increase the anticoagulant activities of Phenindione.Approved, Investigational
Phenprocoumon(4R)-limonene may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with (4R)-limonene.Approved, Investigational
Pindolol(4R)-limonene may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acid(4R)-limonene may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with (4R)-limonene.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with (4R)-limonene.Approved, Investigational
Piromidic acid(4R)-limonene may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pitolisant.Approved, Investigational
Platelet Activating Factor(4R)-limonene may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
Plazomicin(4R)-limonene may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with (4R)-limonene.Approved
PomalidomideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pomalidomide.Approved
Potassium Citrate(4R)-limonene may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
Practolol(4R)-limonene may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with (4R)-limonene.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of (4R)-limonene can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Propacetamol.Approved, Investigational
Propafenone(4R)-limonene may decrease the antihypertensive activities of Propafenone.Approved
Propranolol(4R)-limonene may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with (4R)-limonene.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with (4R)-limonene.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with (4R)-limonene.Vet Approved
Protein C(4R)-limonene may increase the anticoagulant activities of Protein C.Approved
Protein S human(4R)-limonene may increase the anticoagulant activities of Protein S human.Approved
Protocatechualdehyde(4R)-limonene may increase the anticoagulant activities of Protocatechualdehyde.Approved
Prulifloxacin(4R)-limonene may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with (4R)-limonene.Investigational
Puromycin(4R)-limonene may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with (4R)-limonene.Approved
RamiprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Resveratrol.Approved, Experimental, Investigational
Reviparin(4R)-limonene may increase the anticoagulant activities of Reviparin.Approved, Investigational
Ribostamycin(4R)-limonene may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Risedronate.Approved, Investigational
Rivaroxaban(4R)-limonene may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Rofecoxib.Approved, Investigational, Withdrawn
Rosoxacin(4R)-limonene may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rufloxacin(4R)-limonene may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with (4R)-limonene.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with (4R)-limonene.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with (4R)-limonene.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with (4R)-limonene.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with (4R)-limonene.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Serrapeptase.Investigational
Sisomicin(4R)-limonene may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
Sitafloxacin(4R)-limonene may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium Citrate(4R)-limonene may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of (4R)-limonene.Approved
Sotalol(4R)-limonene may decrease the antihypertensive activities of Sotalol.Approved
Sparfloxacin(4R)-limonene may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Spirapril.Approved
Spironolactone(4R)-limonene may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with (4R)-limonene.Investigational
Streptomycin(4R)-limonene may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Sulindac.Approved, Investigational
Sulodexide(4R)-limonene may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with (4R)-limonene.Investigational
SuprofenThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Suxibuzone.Experimental
Tacrolimus(4R)-limonene may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with (4R)-limonene.Approved
Talinolol(4R)-limonene may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with (4R)-limonene.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with (4R)-limonene.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with (4R)-limonene.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with (4R)-limonene.Approved, Investigational
Temafloxacin(4R)-limonene may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tepoxalin.Vet Approved
Terbutaline(4R)-limonene may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with (4R)-limonene.Approved
Tertatolol(4R)-limonene may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tiludronic acid.Approved, Investigational, Vet Approved
Timolol(4R)-limonene may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tixocortol.Approved, Withdrawn
Tobramycin(4R)-limonene may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with (4R)-limonene.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with (4R)-limonene.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with (4R)-limonene.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with (4R)-limonene.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Triamcinolone.Approved, Vet Approved
Triamterene(4R)-limonene may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with (4R)-limonene.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Trolamine salicylate.Approved
Trovafloxacin(4R)-limonene may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
Troxerutin(4R)-limonene may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with (4R)-limonene.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with (4R)-limonene.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with (4R)-limonene.Approved
Warfarin(4R)-limonene may increase the anticoagulant activities of Warfarin.Approved
Ximelagatran(4R)-limonene may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with (4R)-limonene.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with (4R)-limonene.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with (4R)-limonene.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0004321
KEGG Drug
D00194
KEGG Compound
C06099
ChemSpider
389747
ChEBI
15382
ChEMBL
CHEMBL449062
Wikipedia
Limonene

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.457 mg/mLALOGPS
logP4.5ALOGPS
logP3.22ChemAxon
logS-2.5ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity46.48 m3·mol-1ChemAxon
Polarizability17.55 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0173-9100000000-239928f205c8242a700a
GC-MS Spectrum - EI-BGC-MSsplash10-014l-9100000000-507f7afbc17b7c2556e2
GC-MS Spectrum - EI-BGC-MSsplash10-014l-9100000000-1a0c62c6971532ab6782
Mass Spectrum (Electron Ionization)MSsplash10-014l-9100000000-fbf154446f93ee5019c0
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-000i-6900000000-f7ee4bad43b6ccae0ccb
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-00ou-9000000000-51a52c25a98124e179e9
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-0006-9000000000-9655665d3d36755028cc
MS/MS Spectrum - EI-B (HITACHI RMU-6M) , PositiveLC-MS/MSsplash10-0173-9100000000-239928f205c8242a700a
MS/MS Spectrum - EI-B (HITACHI M-80B) , PositiveLC-MS/MSsplash10-014l-9100000000-bc8708fdb2d1955dce92
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-014l-9100000000-1a0c62c6971532ab6782
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as menthane monoterpenoids. These are monoterpenoids with a structure based on the o-, m-, or p-menthane backbone. P-menthane consists of the cyclohexane ring with a methyl group and a (2-methyl)-propyl group at the 1 and 4 ring position, respectively. The o- and m- menthanes are much rarer, and presumably arise by alkyl migration of p-menthanes.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Menthane monoterpenoids
Alternative Parents
Monocyclic monoterpenoids / Branched unsaturated hydrocarbons / Cycloalkenes / Unsaturated aliphatic hydrocarbons
Substituents
P-menthane monoterpenoid / Monocyclic monoterpenoid / Branched unsaturated hydrocarbon / Cycloalkene / Cyclic olefin / Unsaturated aliphatic hydrocarbon / Unsaturated hydrocarbon / Olefin / Hydrocarbon / Aliphatic homomonocyclic compound
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
limonene (CHEBI:15382) / Menthane monoterpenoids, Cyclic monoterpenes (C06099) / Menthane monoterpenoids (LMPR0102090013)

Drug created on September 03, 2013 14:56 / Updated on June 02, 2018 08:14